ESPR Esperion Therapeutics Inc.

41.25
-0.14  -0%
Previous Close 41.39
Open 41.36
Price To Book 13.98
Market Cap 1106525434
Shares 26,824,859
Volume 288,479
Short Ratio
Av. Daily Volume 509,625

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing February 26, 2019.
Bempedoic Acid/ Ezetimibe
Hypercholesterolemia
NDA filed February 20, 2019.
Bempedoic acid
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 2 data due 2H 2019.
Bempedoic Acid/ Ezetimibe (1002-058)
LDL-C and type 2 diabetes
Phase 3 enrolment to be completed 3Q 2019.
Bempedoic Acid (ETC-1002) CLEAR Outcomes
Cardiovascular Diseases

Latest News

  1. Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $217,400 of Shares
  2. Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
  3. Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
  4. Did You Miss Esperion Therapeutics’s (NASDAQ:ESPR) Impressive 225% Share Price Gain?
  5. New Research Coverage Highlights Advance Auto Parts, AxoGen, Encana, Federal Signal, Nelnet, and Esperion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2019
  6. Esperion to Participate in Upcoming Investor Conferences
  7. Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions
  8. Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4
  9. Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results
  10. Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
  11. Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  12. Update in Lawsuit for Investors in NASDAQ: ESPR shares against Esperion Therapeutics, Inc. announced by Shareholders Foundation
  13. For Esperion Therapeutics, 2019 Could Be a Big Year
  14. Update: Lawsuit for Investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced by Shareholders Foundation
  15. Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
  16. All the Pre-JPM News Healthcare Investors Need to Know
  17. Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today
  18. Esperion to receive $300 million in upfront payments in deal with Daiichi Sankyo
  19. Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe